BLOG

Wednesday, August 28, 2019

Sun Pharma gains 5% as Sebi finds no merit in allegation of fraud

HDFC Securities has 'buy' rating on Sun Pharma with a 12-month target price of Rs 545 as the brokerage expects a recovery in the profitability (24 per cent margin) by FY21E.

from Home Page https://ift.tt/2zuAICe
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...